Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Caicun Zhou, MD
CONTACT
Lead
Shanghai Huaota Biopharmaceutical Co., Ltd.
The random stratification factors of this study are as follows: Disease stage (Stage IIIB/IIIC vs Stage IV); PD-L1 expression score indicator (Tumor Proportion Score, TPS): \<1%, 1%-49%, ≥50%; Hepatic or brain metastasis (Yes vs No). This trial adopts the RECIST v1.1 criteria to conduct regular tumor response assessments for the subjects. Within 1 year (365 days) after the first dose, tumor assessments will be performed at Week 6 (±7 days), Week 12 (±7 days), and then every 9 weeks (±7 days) thereafter; after 1 year, assessments will be conducted every 12 weeks (±7 days). If a subject discontinues study treatment due to reasons other than disease progression or death, tumor assessments should continue according to the fixed schedule until disease progression or study termination (whichever occurs later), initiation of new anti-tumor therapy, loss to follow-up, death, withdrawal of informed consent, or study completion, whichever occurs first. At least 4 weeks after the first documentation of objective response, the objective response should be confirmed by re-assessment (in cases of clinical stability, the confirmation can be performed at the next scheduled assessment time point). After the first documented radiological progression, if the investigator determines that the subject can still benefit from continued treatment and meets the criteria for continued treatment specified in the protocol, the subject may maintain the original treatment regimen until no clinical benefit is observed (assessed by the investigator). If a subject withdraws from the study treatment due to reasons other than those mentioned above (e.g., occurrence of intolerable adverse events, completion of 24 months of HB0025 or tislelizumab treatment, or other reasons necessitating treatment discontinuation), a tumor assessment should be performed prior to study termination. The investigator may conduct unscheduled tumor assessments (with an interval of at least 4 weeks from the previous assessment) when disease progression is suspected or other necessary circumstances arise. The sponsor will collect all imaging data of the subjects for BICR assessment.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
